rAAV Capsid Purification via Preferential Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying full recombinant adeno-associated virus (rAAV) capsids from mixtures with empty capsids are inefficient due to similar physical properties, leading to high costs and product losses, and existing purification techniques like chromatography and ultracentrifugation are not suitable for large-scale clinical production.
Innovation Solution
The method involves preferential crystallization of full rAAV capsids using a crystallization solution with specific conditions of precipitant concentration, salt concentration, and pH, allowing for the separation of full capsids from empty capsids, which are then removed to purify the full capsids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chromatography or ultracentrifugation is used to purify full rAAV capsids from empty capsids, then purification is achieved, but the process incurs high costs, long processing times, additional steps, and product losses
Solution Approach 1:
The invention changes the physical-chemical parameters of the solution by adjusting pH to specific ranges (pH 3.0-4.0 for empty capsid removal, pH 7.0-8.0 for full capsid precipitation) and ionic strength through salt concentration adjustments. These parameter changes exploit the different isoelectric points and solubility characteristics of full versus empty capsids, enabling selective purification without complex chromatography or ultracentrifugation procedures
Solution Approach 2:
The invention utilizes phase transition of the capsid proteins through controlled precipitation. By adjusting pH and ionic strength, empty capsids are selectively solubilized and removed in the supernatant phase, while full capsids remain as a precipitate that can be easily collected by centrifugation. This phase transition approach replaces time-consuming chromatography with simple centrifugation steps
2Ease of manufacture
If empty capsids are not removed from the mixture, then the production process is simpler, but the antigen load increases and immune responses are reduced
Solution Approach 1:
The invention performs preliminary separation of empty capsids before final product formulation. By conducting the pH-adjusted precipitation and centrifugation steps early in the purification process, empty capsids are removed in advance, preventing them from contributing to antigen load and immune responses in the final therapeutic product
Solution Approach 2:
The invention extracts and removes the harmful component (empty capsids) from the mixture through selective solubilization at low pH. The empty capsids are taken out in the supernatant phase after centrifugation, leaving behind a purified full capsid preparation with reduced antigen load and minimized immune response risk
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively purifies full rAAV capsids, reducing the antigen load and immune responses, and is more cost-effective and efficient than existing methods, making it suitable for large-scale clinical production.
Implementation Method 1
full capsids of recombinant adeno-associated virus vectors (rAAVs) containing recombinant therapeutic genes suitable for gene therapies are preferentially crystallized from a mixture that contains both full rAAV capsids and empty rAAV capsids
Implementation Method 2
mixing the mixture with one or more crystallization solution, wherein the crystallization solution comprising a pre-determined set of conditions of precipitant concentration, salt concentration, and pH
Data Source
AI summary
Methods of purifying full capsids of recombinant adeno-associated virus vectors (rAAVs) from a solution containing a mixture of full and empty capsids are described. Typically, methods use crystallization reagents and conditions that preferentially crystalize full rAAV capsids over empty rAAV capsids. Specifically, crystallization reagents and conditions that preferentially crystalize full rAAV5 or rAAV8 capsids over their corresponding empty rAAV capsids are described. The resulting crystals containing mostly or exclusively full rAAV capsids are particularly suited for use in gene therapy. Methods of storing and reconstituting the crystals of full rAAV capsids in preparation for administering to a subject in need thereof are also provided.